Quarterly ResultAug 6, 2026, 08:09 AM
Prime Medicine Issues Going Concern Warning; Q2 Net Loss $(42.1)M
AI Summary
Prime Medicine, Inc. reported its Q2 2026 financial results, highlighting a significant going concern warning from management, indicating substantial doubt about the company's ability to continue operations for the next 12 months. The biotechnology company posted a net loss of $(42.1) million for the quarter, an improvement from the prior year, but its cash and short-term investments stood at $95.1 million, with an accumulated deficit nearing $980 million. Total assets and stockholders' equity also saw notable declines compared to year-end 2025.
Key Highlights
- Management concluded substantial doubt exists about Prime Medicine's ability to continue as a going concern.
- Net loss for Q2 2026 was $(42.1) million, an improvement from $(52.6) million in Q2 2025.
- Cash, cash equivalents, and short-term investments totaled $95.1 million as of June 30, 2026.
- Accumulated deficit reached $979.6 million as of June 30, 2026.
- Total assets decreased to $249.0 million from $342.7 million at December 31, 2025.
- Total stockholders' equity declined to $39.8 million from $120.9 million at December 31, 2025.
- Research and development expenses decreased to $33.4 million in Q2 2026 from $41.4 million in Q2 2025.
- Net cash used in operating activities for the six months ended June 30, 2026, was $(83.8) million.
Price Impact
More from PRME